A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19

A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19

Abstract Introduction Hyperinflammatory state has a role in the pathogenesis of COVID‐19. Anakinra could reduce inflammation and help to combat the condition. In this study, we aimed to assess the safety and efficacy of anakinra (PerkinRA®) in severe COVID‐19. Method The study was an open‐label, ran...

Full description

Bibliographic Details
Main Authors: Amir Behnam Kharazmi, Omid Moradi, Mehrdad Haghighi, Mehran Kouchek, Alireza Manafi‐Rasi, Masoomeh Raoufi, ‪Simin Dokht Shoaei, Fahimeh Hadavand, Mahmood Nabavi, Mir Mohammad Miri, Sara Salarian, Seyedpouzhia Shojaei, Shayesteh Khalili, Mohammad Sistanizad, Setayesh Sadeghi, Amirhossein Karagah, Saemeh Asgari, Morteza Jaffaraghaei, Shahram Araghi
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Immunity, Inflammation and Disease
Subjects:
acute respiratory distress syndrome
anakinra
coronavirus
COVID‐19
inflammation
interleukin‐1 inhibitor
Online Access:https://doi.org/10.1002/iid3.563

Internet

https://doi.org/10.1002/iid3.563

Similar Items